Im­mu­nicum's den­drit­ic cell ther­a­py flunks co-pri­ma­ry end­point in 'pos­i­tive' PhII

Im­mu­nicum’s im­mune prim­ing den­drit­ic cell in­jec­tion has missed the mark on a Phase II ex­plorato­ry tri­al in metasta­t­ic kid­ney can­cer, but that’s not stop­ping the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER